SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?


To: GregS who wrote (1731)2/15/1999 3:57:00 PM
From: Anthony@Pacific  Read Replies (1) | Respond to of 2135
 
If there is a question and answer session I need IN!!!



To: GregS who wrote (1731)2/15/1999 6:48:00 PM
From: Henry Niman  Respond to of 2135
 
Over the weekend, Bloomberg came out with a Q&A report on ENMD's compounds. This morning BBIOY announced that its anti-angiogenesis compound, Marimastat, did not achieve endpoints in Pancreatic Cancer trial. Details linked to Anti-Angiogenesis Table in New Therapeutics section of biocognizance.com